The Effect of Human Umbilical Cord Mesenchymal Stem Cells and Exosomes on the Healing of Postoperative Pain and Periapical Lesions in the Treatment of Apical Periodontitis: Randomized Controlled Clinical Study

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age9-15
SponsorTC Erciyes University

About this trial

The main purpose of this study is to evaluate the effect of Mesenchymal Stem Cells (MSCs) isolated from the umbilical cord and exosomes derived from these cells on the success of the treatment in the regenerative endodontic treatment of necrotic open apex molar teeth.

Regenerative endodontic treatment aims to disinfect root canals and revascularize pulp tissue. Our goals in this study are; obtaining umbilical cord-derived MSCs, obtaining exosomes derived from umbilical cord MSCs, selecting patients with molar teeth with necrotic open apex and periapical lesion, initiation of regenerative endodontic treatment and disinfection of root canals, induction of bleeding in the periapical region and formation of a blood clot in the root canal in the 1st patient group, in the 2nd patient group, umbilical cord-derived MSCs were placed in the root canals without bleeding in the periapical region, in the 3rd patient group, placement of exosomes from umbilical cord-derived MSCs into the root canals without causing bleeding in the periapical region, it is the follow-up of patients at regular intervals for up to 1 year after treatment is completed.

Eligibility criteria

Qualifiers

Molar teeth with open apex

Teeth with apical periodontitis

Teeth for which prosthetic restoration is not planned

Patients between the ages of 9-15 without any significant health problems

Disqualifiers

Individuals with systemic diseases and allergic reactions

Severely damaged teeth

Previous root canal treatment has been performed on the tooth.

Use of antibiotics, anti-inflammatory, and painkillers in the last two weeks

Trial design

Treatments tested in this trial

  • Stem Cell Product
  • Bleeding and clots

Treatment groups

45 Participants
are divided into 3 treatment groups

Sponsors and collaborators